



# Kilitch Drugs (India) Ltd.

Admn. Off. : Ujagar Industrial Estate, Waman T. Patil Marg, Deonar, Mumbai - 400 088.  
Tel. : +91-22-6703 3322 • Fax : +91-22-6703 1658  
C-301/2, M. I. D. C., T.T.C. Indl. Area, Pawane Village, Thane - 400 701 Maharashtra.  
Regd. Off. : Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912.  
& Factory Email : info@kilitch.com • website : www.kilitch.com

## KILITCH DRUGS (INDIA) LIMITED

Regd. Office. - C-301/2, TTC Industrial Area, MIDC, Pawane, Navi Mumbai - 400705

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2008

(Rs. In Lacs)

SR. NO.	PARTICULARS	Quarter ended 30.9.2008 Unaudited	Quarter ended 30.9.2007 Unaudited	Six Month ended on 30.9.2008 Unaudited	Six Month ended on 30.9.2007 Unaudited	Year ended 31.3.2008 Audited
1	Sales & Operating Income (gross)	3,752.99	2,790.09	7,296.55	5,209.71	12,700.05
	Less: Duties & Taxes	128.00	43.47	164.42	71.99	982.39
	Sales & Operating Income (net)	3,624.99	2,746.62	7,132.13	5,137.72	11,717.66
2	Other Income	1.36	-	2.86	0.06	14.11
3	Total Expenditure					
	a) (Increase)/Decrease in Stock-in-Trade & WIP	40.09	(10.77)	30.47	(15.39)	(180.99)
	b) Consumption of materials	2,620.50	1,772.45	5,234.40	3,395.28	8,218.13
	c) Employee Costs	94.58	47.80	180.20	91.07	221.96
	d) Other Expenses	45.36	395.19	84.81	751.19	1,172.07
4	Interest	99.75	86.70	186.36	118.32	400.46
5	Depreciation	143.69	112.50	279.21	224.50	627.76
6	Profit before tax	582.38	342.75	1,139.54	572.81	1,272.38
7	Tax Expense	76.24	32.75	131.24	53.25	154.36
8	Net Profit	506.14	310.00	1,008.30	519.56	1,118.02
9	Paid up Equity share Capital (face value of Rs.10 per share)	1,320.21	1,320.21	1,320.21	1,320.21	1,320.21
10	Reserves excluding Revaluation Reserves	-	-	-	-	3,811.60
11	Earnings Per Share (EPS)					
	- Basic EPS(Rs.)	3.83	2.35	7.64	3.94	9.34
	- Diluted EPS(Rs.)					8.47
12	Public Shareholding					
	- Numbers of Shares	4665587	44099870	4665587	44099870	4665587
	- Percentage of Shareholding	35.34%	33.22%	35.34%	33.22%	35.34%

#### Notes :

- The above results after being reviewed by the Audit Committee, have been approved and taken on record by the Board of Directors at its meeting held on 27.10.2008, and are subject to Limited Review by the Auditors.
- The profits are higher during the current quarter, as compared to previous period, due to the commencement of operations at the manufacturing facility at Himachal Pradesh. During the current quarter, this facility has reached a capacity utilisation of 40%.
- Investors complaints for the quarter (in Nos.) : d/s as on 01.07.08 - NIL; Received during the Qtr. - 4; Resolved during the Qtr. - 4; o/s as on 30.09.08 - NIL
- The Company has only one Primary Reportable Segment viz. 'pharmaceuticals'.
- The prior period figures have been regrouped / reclassified, wherever required.
- The Company has issued 29,00,000 warrants @ Rs. 120/- each on which 10% money has been received as a application money.

By and on Behalf of the Board  
For Kilitch Drugs (India) Ltd.

Mukund P. Mahta  
Managing Director



Place : Mumbai  
Date : 27.10.2008